Witnesses Seek 15% Boost For NCI In 1998 as First Step to 100% Raise Over 5 Years
In Brief: visco Named to Cancer Policy Board; Foundation Pledges $6.5 Million to Karmanos
In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform
Patient Advocates; NBCC Delivers 2.6M Signatures, demands 2.6Billion
NIH director; Targets Increases Favor Established Researchers
Pharmaceutical Industry: IVAX Official Broder Objects To Orphan Drug Policies of FDA
National Academy elects New Members
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Scaling excellence: How City of Hope is transforming cancer care delivery
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI
